Leerink Partnrs Has Bullish Outlook for FDMT FY2024 Earnings

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) - Investment analysts at Leerink Partnrs boosted their FY2024 EPS estimates for 4D Molecular Therapeutics in a report issued on Monday, January 13th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will earn ($2.90) per share for the year, up from their previous estimate of ($2.95). The consensus estimate for 4D Molecular Therapeutics' current full-year earnings is ($2.89) per share. Leerink Partnrs also issued estimates for 4D Molecular Therapeutics' Q4 2024 earnings at ($0.81) EPS and FY2025 earnings at ($3.35) EPS.

FDMT has been the subject of a number of other research reports. Leerink Partners dropped their price target on 4D Molecular Therapeutics from $31.00 to $27.00 and set an "outperform" rating for the company in a research report on Monday. Bank of America dropped their target price on shares of 4D Molecular Therapeutics from $79.00 to $46.00 and set a "buy" rating for the company in a research report on Wednesday, December 18th. HC Wainwright reissued a "buy" rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a report on Monday. Royal Bank of Canada dropped their price objective on shares of 4D Molecular Therapeutics from $40.00 to $39.00 and set an "outperform" rating for the company in a report on Thursday, November 14th. Finally, Chardan Capital reissued a "buy" rating and issued a $39.00 target price on shares of 4D Molecular Therapeutics in a research note on Thursday, November 14th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company's stock. According to MarketBeat.com, 4D Molecular Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $38.56.

4D Molecular Therapeutics Stock Performance

4D Molecular Therapeutics stock traded up $0.16 during midday trading on Wednesday, hitting $5.04. 626,938 shares of the company's stock were exchanged, compared to its average volume of 784,338. The company has a market cap of $232.99 million, a P/E ratio of -1.77 and a beta of 2.81. The stock has a 50-day moving average price of $6.87 and a two-hundred day moving average price of $11.77. 4D Molecular Therapeutics has a 52-week low of $4.68 and a 52-week high of $36.25.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of FDMT. Rhumbline Advisers grew its position in 4D Molecular Therapeutics by 14.2% during the 2nd quarter. Rhumbline Advisers now owns 72,933 shares of the company's stock worth $1,531,000 after acquiring an additional 9,062 shares during the last quarter. Quest Partners LLC boosted its stake in shares of 4D Molecular Therapeutics by 17,409.1% during the second quarter. Quest Partners LLC now owns 5,778 shares of the company's stock valued at $121,000 after purchasing an additional 5,745 shares during the period. American Century Companies Inc. bought a new position in shares of 4D Molecular Therapeutics in the second quarter worth approximately $268,000. Parallel Advisors LLC increased its stake in shares of 4D Molecular Therapeutics by 59,833.3% in the second quarter. Parallel Advisors LLC now owns 19,778 shares of the company's stock worth $415,000 after buying an additional 19,745 shares during the period. Finally, Sofinnova Investments Inc. raised its holdings in 4D Molecular Therapeutics by 36.8% during the 2nd quarter. Sofinnova Investments Inc. now owns 271,155 shares of the company's stock valued at $5,692,000 after buying an additional 72,969 shares during the last quarter. 99.27% of the stock is owned by institutional investors.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.